Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials.
clinical trials
endometrial cancer
immune checkpoint inhibitors
immunotherapy
microsatellite stable
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
received:
27
05
2022
revised:
13
07
2022
accepted:
28
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Recurrent microsatellite stable (MSS) endometrial cancer has poor response to conventional therapy and limited efficacy with immune checkpoint monotherapy. We conducted a retrospective study of recurrent MSS endometrial cancer patients enrolled in immunotherapy-based clinical trials at MD Anderson Cancer Center between 1 January 2010 and 31 December 2019. Patients were evaluated for radiologic response using RECIST 1.1 criteria, progression-free survival (PFS), and overall survival (OS). Thirty-five patients were treated with immune checkpoint inhibitors: 8 with monotherapy, 17 with immunotherapy (IO) in combination with another IO-only, and 10 with IO in combination with non-IO therapy. Among those treated with combination IO plus non-IO therapy, one had a partial response but 50% had clinical benefit. Patients who received combination IO plus non-IO therapy had improved PFS compared to those who received monotherapy (HR 0.56, 95% CI 0.33-0.97;
Identifiants
pubmed: 35954359
pii: cancers14153695
doi: 10.3390/cancers14153695
pmc: PMC9367373
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : T32CA101642
Pays : United States
Organisme : NCI NIH HHS
ID : CA098258
Pays : United States
Organisme : Dr. Henry R. Shibata Fellowship Award/Cedars Cancer Foundation
ID : NA
Références
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Cancers (Basel). 2020 Jun 09;12(6):
pubmed: 32526888
Cancer J. 2018 Jan/Feb;24(1):47-53
pubmed: 29360728
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Oncoimmunology. 2014 Dec 15;3(10):e956579
pubmed: 25941577
J Clin Oncol. 2017 Aug 1;35(22):2535-2541
pubmed: 28489510
Cancer Immunol Res. 2018 Jan;6(1):14-24
pubmed: 29097422
Gynecol Oncol. 2020 Jun;157(3):729-732
pubmed: 32173047
Oncol Lett. 2017 Sep;14(3):3297-3301
pubmed: 28927079
JAMA Oncol. 2020 Nov 01;6(11):1766-1772
pubmed: 33001143
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2019 Oct 20;37(30):2786-2794
pubmed: 31461377
J Hematol Oncol. 2019 Mar 12;12(1):27
pubmed: 30866992
N Engl J Med. 2020 Nov 19;383(21):2053-2064
pubmed: 33207095
Expert Rev Anticancer Ther. 2009 Jul;9(7):905-16
pubmed: 19589030
Br J Cancer. 2018 Feb 6;118(3):312-324
pubmed: 29123260
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
J Clin Oncol. 2020 Jan 20;38(3):214-222
pubmed: 31765263
JAMA Oncol. 2021 May 01;7(5):739-743
pubmed: 33599686
Cancers (Basel). 2020 Feb 08;12(2):
pubmed: 32046278
Signal Transduct Target Ther. 2021 Feb 20;6(1):72
pubmed: 33608497
J Clin Oncol. 2020 Sep 10;38(26):2981-2992
pubmed: 32167863
Cancer Manag Res. 2020 Jul 22;12:6123-6135
pubmed: 32801862
Gynecol Oncol. 2010 May;117(2):373-81
pubmed: 20223510
Cancer Discov. 2019 May;9(5):646-661
pubmed: 30777870
Cell. 2007 Jan 12;128(1):157-70
pubmed: 17218262
Nat Immunol. 2019 Sep;20(9):1231-1243
pubmed: 31358999
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Cancer Sci. 2019 Sep;110(9):2894-2904
pubmed: 31348579
EMBO Mol Med. 2009 Sep;1(6-7):315-22
pubmed: 20049735
Nat Med. 1996 Oct;2(10):1096-103
pubmed: 8837607
Hum Pathol. 2008 Jan;39(1):116-25
pubmed: 17949789
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652